Opiate Withdrawal Syndrome Clinical Trial
Official title:
Ibogaine to Determine Maximum Tolerated Dose (MTD) or Treat-to-Target Dose (TTD) for the Evaluation of Efficacy and Safety
Study DMX-IB 201 is a Phase 1/2a study of ibogaine consisting of an initial single ascending dose escalation stage to determine the maximum tolerated dose (MTD) or treat-to-target dose (TTD) in healthy volunteers, followed by a randomized, double-blind, placebo-controlled proof of concept stage to demonstrate the efficacy, safety and tolerability of the selected dose in opioid-dependent patients who seek medically supervised opioid withdrawal
Detailed description restricted as elements of this trial are part of a Phase 1 clinical trial. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03975192 -
Neurostimulation for Opiate Withdrawal in the PICU
|
N/A | |
| Completed |
NCT03521960 -
Buspirone for Opioid Tapering
|
Phase 1 | |
| Enrolling by invitation |
NCT03012373 -
Efficacy of Acupuncture as an Adjunct to Methadone Treatment Services for Heroin Addicts
|
N/A | |
| Completed |
NCT01945736 -
Pharmacokinetics of Multiple Dose Methadone in Children Treated for Opiate Withdrawal
|
||
| Not yet recruiting |
NCT03397212 -
Treatment of Withdrawal Symptoms With NADA Acupuncture in Chronic Pain Patients
|
Phase 4 | |
| Recruiting |
NCT05995535 -
Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal
|
Phase 2 | |
| Completed |
NCT05569031 -
Treatment of Withdrawal Symptoms and Prevention of Relapse in Patients With Tramadol Abuse
|
Phase 4 | |
| Completed |
NCT03971097 -
The Effect of Self-Forgiveness on Self-Stigma in Addiction.
|
N/A | |
| Completed |
NCT03077932 -
An App to Aid in Transitioning Off Opioid Medication
|
N/A |